Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas

European Urology

Volumn 52, Issue 4, 2007, Pages 1147-1155

  Kawai, Yoshihisa ^a   Sakano, Shigeru ^a   Korenaga, Yoshihito ^a   Eguchi, Satoshi ^a   Naito, Katsusuke ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Neoplasm staging; Renal cell carcinoma; Single nucleotide polymorphism; Survival; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; PARAMETER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548256390     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.073     Document Type: Article

References (29)

1. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4-25
2. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
3. Lu H., Shu X.O., Cui Y., et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65 (2005) 5015-5019
4. Paradis V., Lagha N.B., Zeimoura L., et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 436 (2000) 351-356
5. Jacobsen J., Rasmuson T., Grankvist K., and Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal call carcinoma. J Urol 163 (2000) 343-347
6. Jacobsen J., Grankvist K., Rasmuson T., Bergh A., Landberg G., and Ljungberg B. Expression of endothelial growth factor protein in human renal cell carcinoma. BJU Int 93 (2004) 297-302
7. Watson C.J., Webb N.J., Bottomley M.J., and Brenchley P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12 (2000) 1232-1235
8. Koukourakis M.I., Papazoglou D., Giatromanolaki A., Bougioukas G., Maltezos E., and Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 (2004) 293-298
9. Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13 (2002) 260-264
10. Mohammadi M., Ollier W.E., and Hutchinson I.V. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated PBM cells. Hum Immunol 64 (2003) S125
11. Awata T., Inoue K., Kurihara S., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639
12. Awata T., Kurihara S., Takata N., et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333 (2005) 679-685
13. Yang B., Cross D.F., Ollerenshaw M., Millward B.A., and Demaine A.G. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 17 (2003) 1-6
14. McCarron S.L., Edwards S., Evans P.R., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62 (2002) 3369-3372
15. Howell W.M., Bateman A.C., Turner S.J., Collins A., and Theaker J.M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumor development in cutaneous malignant melanoma. Genes Immun 3 (2002) 229-232
16. Jin Q., Hemminki K., Enquist K., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11 (2005) 3647-3653
17. Linehan W.M. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol 170 (2003) 593-594
18. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
19. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
20. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18 (1999) 2343-2350
21. Schmidt L., Junker K., Weirich G., et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58 (1998) 1719-1722
22. Korenaga Y., Naito K., Okayama N., et al. Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer 117 (2005) 431-434
23. Sakano S., Kumar R., Larsson P., et al. A single-nucleotide polymorphism in the XPG gene, and tumor stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int 97 (2006) 847-851
24. Brogan I.J., Khan N., Isaac K., Hutchinson J.A., Pravica V., and Hutchinson I.V. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60 (1999) 1245-1249
25. Sakano S., Berggren P., Kumar R., et al. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int J Cancer 104 (2003) 98-103
26. Schips L., Dalpiaz O., Lipsky K., et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 51 (2007) 168-174
27. Kim E.J., Jeong P., Quan C., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65 (2005) 70-75
28. Abe A., Sato K., Habuchi T., et al. Single nucleotide polymorphisms in the 3′ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med 198 (2002) 181-190
29. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434